Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$28.81 -0.1%	$29.98	$22.90 ▼ $36.45	$4.75B	0.47	1.73 million shs	2.94 million shs
BCRX BioCryst Pharmaceuticals	$9.36 -3.1%	$9.96	$6.02 ▼ $11.31	$1.96B	1.11	3.02 million shs	7.45 million shs
CLDX Celldex Therapeutics	$20.29 -4.2%	$20.16	$14.40 ▼ $47.00	$1.35B	1.33	942,945 shs	2.47 million shs
LGND Ligand Pharmaceuticals	$114.15 -1.3%	$107.71	$81.74 ▼ $129.90	$2.20B	0.83	118,164 shs	327,870 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.07%	-0.96%	-3.65%	-13.25%	+17.26%
BCRX BioCryst Pharmaceuticals	-3.11%	-7.33%	-11.36%	+19.08%	+51.46%
CLDX Celldex Therapeutics	-4.16%	-1.02%	+8.74%	+1.81%	-43.81%
LGND Ligand Pharmaceuticals	-1.33%	+0.07%	+13.93%	+6.07%	+46.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.8988 of 5 stars	4.4	3.0	4.2	2.9	2.5	1.9
BCRX BioCryst Pharmaceuticals	4.4326 of 5 stars	4.4	2.0	4.2	1.9	1.7	0.6
CLDX Celldex Therapeutics	2.5912 of 5 stars	4.4	3.0	0.0	2.1	0.0	0.0
LGND Ligand Pharmaceuticals	4.6929 of 5 stars	3.5	3.0	4.4	1.7	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.00	38.84% Upside
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	76.88% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	146.97% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	28.03% Upside

Current Analyst Ratings Breakdown

Latest CLDX, ALKS, LGND, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.05	$2.65 per share	10.87	$9.05 per share	3.18
BCRX BioCryst Pharmaceuticals	$450.71M	4.35	N/A	N/A	($2.30) per share	-4.07
CLDX Celldex Therapeutics	$7.02M	191.86	N/A	N/A	$11.26 per share	1.80
LGND Ligand Pharmaceuticals	$167.13M	13.18	$1.61 per share	71.04	$43.95 per share	2.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.78	21.03	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.12	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	30.77	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest CLDX, ALKS, LGND, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CLDX Celldex Therapeutics	N/A	21.67	21.67
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
BCRX BioCryst Pharmaceuticals	4.80%
CLDX Celldex Therapeutics	4.40%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

CLDX, ALKS, LGND, and BCRX Headlines

Recent News About These Companies

LGND Ligand Pharmaceuticals Incorporated - Seeking Alpha

June 26 at 6:51 PM | seekingalpha.com

Andrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 26 at 7:16 AM | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in Stock

June 25 at 4:03 AM | marketbeat.com

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

June 24, 2025 | seekingalpha.com

Advisor Resource Council Makes New $2.24 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 21, 2025 | marketbeat.com

SG Americas Securities LLC Acquires 5,201 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 21, 2025 | marketbeat.com

Chicago Capital LLC Has $58.30 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 17, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 16, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in Stock

June 13, 2025 | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 Shares

June 12, 2025 | marketbeat.com

LGND Makes Bullish Cross Above Critical Moving Average

June 11, 2025 | nasdaq.com

Ligand Announces 2025 Investor Day in New York City

June 11, 2025 | globenewswire.com

GAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 10, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from Brokerages

June 10, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.

June 7, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 Shares

June 3, 2025 | marketbeat.com

Andrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 3, 2025 | insidertrades.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 3, 2025 | marketbeat.com

Summit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 1, 2025 | marketbeat.com

Kings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31, 2025 | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver

CLDX, ALKS, LGND, and BCRX Company Descriptions

Alkermes NASDAQ:ALKS

$28.81 -0.02 (-0.07%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$29.10 +0.29 (+1.02%)

As of 06/27/2025 07:08 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.36 -0.30 (-3.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.48 +0.12 (+1.29%)

As of 06/27/2025 07:55 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$20.29 -0.88 (-4.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.27 -0.02 (-0.07%)

As of 06/27/2025 05:59 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$114.15 -1.54 (-1.33%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$114.10 -0.06 (-0.05%)

As of 06/27/2025 05:18 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time